Patents Examined by Nelson B Moseley, II
  • Patent number: 11365261
    Abstract: The disclosure provides binding proteins that bind CD38 polypeptides, e.g., human and cynomolgus monkey CD38 polypeptides. For example, the binding proteins can be monospecific, bispecific, or trispecific binding proteins with at least one antigen binding domain that binds a CD38 polypeptide. The disclosure also provides methods for making binding proteins that bind CD38 polypeptides and uses of such binding proteins.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: June 21, 2022
    Assignee: SANOFI
    Inventors: Béatrice Cameron, Tarik Dabdoubi, Cendrine Lemoine, Catherine Prades
  • Patent number: 11365264
    Abstract: Methods for diagnosing or treating immune disorders in a subject are provided. The methods are based on the detection or modulation of Refractory state Inducing Factor (RIF).
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: June 21, 2022
    Inventors: Jacques Theze, Thierry Rose, Florence Bugault
  • Patent number: 11359016
    Abstract: Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: June 14, 2022
    Assignee: ADAGENE INC.
    Inventors: Peter Peizhi Luo, Fangyong Du, Zhongzong Pan, Guizhong Liu
  • Patent number: 11345733
    Abstract: This invention relates to NPC-1 antigen on the MUC5AC protein and 16C3 antigen on CEACAM5 and CEACAM6 proteins, and 31.1 epitope on the A33 protein are differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages. Further, NPC-1, 16C3, and/or 31.1 epitope specific antibodies and diagnostic and therapeutic methods of use.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: May 31, 2022
    Inventors: Xiulian Du, Janos Luka, Lewis Joe Stafford, Mark Semenuk, Xue-Ping Wang, Judith Kantor, Andrew Bristol
  • Patent number: 11345731
    Abstract: The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: May 31, 2022
    Assignees: BioNTech Cell & Gene Therapies GmbH, TRON-Translationale Onkologie An Der Universitatsmedzin Der Johannes Gutenberg-Universitat Mainz, Ganymed Pharmaceuticals AG
    Inventors: Ugur Sahin, Özlem Türeci, Petra Simon, Tana Omokoko, Holger Hoff, Ralf-Holger Voss, Andrea Breitkreuz, Kathleen Hobohm, Karolina Anna Mroz
  • Patent number: 11332512
    Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide.
    Type: Grant
    Filed: October 1, 2021
    Date of Patent: May 17, 2022
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 11311608
    Abstract: Autophagy is the principal catabolic response to nutrient starvation. However, excessive autophagy can be cytotoxic or cytostatic, and contribute to cell death, but its mechanism of induction remains elusive. Here, it was demonstrated that prolonged arginine starvation by ADI-PEG20 induced an autophagy-dependent death of argininosuccinate synthetase 1 (ASS1)-deficient breast cancer cells. Consequently, arginine depleting agents such as ADI-PEG20 may be used in methods for killing one or more argininosuccinate synthetase 1 (ASS1)-deficient breast cancer cells. Further, abundance of ASS1 was either low or absent in more than 60% of 149 random breast cancer biosamples, which could be exploited as candidates for arginine starvation therapy.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: April 26, 2022
    Assignee: CITY OF HOPE
    Inventors: David K. Ann, Yun-Ru Chen, Fuming Qiu
  • Patent number: 11312770
    Abstract: The present invention is directed to bispecific, heterodimeric checkpoint antibodies.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: April 26, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal, Umesh Muchhal
  • Patent number: 11298433
    Abstract: Provided herein are methods, kits, and compositions for stratifying and treating subjects, e.g., subjects having cancer. In some examples, the methods involve use of a radiolabelled heavy chain variable domain derived from a heavy chain antibody (VHH), or a functional fragment thereof, as both a screening agent and a treatment agent. In some examples, the VHH, or a functional fragment thereof, that is radiolabelled with a radioisotope that is both a ?-emitter and ?-emitter.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: April 12, 2022
    Inventors: Tony Lahoutte, Matthias D'Huyvetter, Jens De Vos, Nick Devoogdt
  • Patent number: 11291722
    Abstract: The present invention relates to a vaccine composition comprising cyclic peptides of the present invention, antibodies to cyclic peptides, or an anticancer composition comprising them, and the vaccine composition of the present invention exhibit an inhibitory activity for metastasis of cancer. In addition, the antibodies of the present invention bind to the tumor-specific antigen TM4SF5 with high affinity, and significantly inhibit the growth, metastasis and invasion of cancer cells expressing the tumor-specific antigen TM4SF5, and thus can be used for diagnosis, prevention or treatment of various cancers expressing TM4SF5.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: April 5, 2022
    Inventors: Hyung Joo Kwon, Yong Sung Kim
  • Patent number: 11286311
    Abstract: Disclosed are a CH3 domain variant pair of an antibody, a method for preparing same, and a use thereof. A mutation is induced in the CH3 domain so as to improve a yield of forming a heterodimer heavy chain constant region of an antibody. The CH3 domain heterodimer forms a heterodimer heavy chain constant region with a high efficiency of 90 to 95% or more and also has outstanding heat stability. A heterodimer heavy chain constant region including the CH3 domain heterodimer can construct a bispecific monoclonal antibody which simultaneously recognizes two kinds of antigens. The CH3 domain heterodimer and the bispecific antibody or fusion protein of an antibody constant region comprising same can be usefully applied to the treatment or prevention of a disease associated with a target antigen or a target protein.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: March 29, 2022
    Assignee: Ajou University Industry-Academic Cooperation Foundation
    Inventors: Yong Sung Kim, Hye Ji Choi, Eun Sil Sung
  • Patent number: 11273217
    Abstract: Mesothelioma growth inhibitory effect of standard cisplatin-pemetrexed concomitant therapy is potentiated by combination with an anti-CD26 antibody. A high therapeutic effect and excellent safety is obtained by the concomitant use of an anti-CD26 antibody and gemcitabine. By conjugating an anti-CD26 antibody (YS110) with triptolide via a divalent cross-linking agent for concomitant therapy using the anti-CD26 antibody, a novel antibody-drug conjugate (Y-TR1) very highly effective for CD26-positive malignant mesothelioma cells has been successfully obtained.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: March 15, 2022
    Assignee: Y's AC Co., Ltd.
    Inventors: Taketo Yamada, Mutsumi Hayashi, Kohji Yamada, Chikao Morimoto, Toshihiro Okamoto, Yutaro Kaneko
  • Patent number: 11267857
    Abstract: The present invention relates, in part, to, chimeric proteins which include the extracellular domain of colony stimulating factor 1 receptor (CSF1R) and their use in the treatment of diseases, such as immunotherapies for cancer and/or an inflammatory disease.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: March 8, 2022
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • Patent number: 11261255
    Abstract: Provided are anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-EGFR antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: March 1, 2022
    Assignee: Shanghai Henlius Biotech, Inc.
    Inventors: Weidong Jiang, Pei-Hua Lin
  • Patent number: 11260116
    Abstract: The present application relates to vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier. Further described are methods and use of the vaccine composition for inducing an antibody immune response and/or a cell-mediated immune response to the neoantigen, as well as methods and uses of the vaccine compositions in the treatment of cancer.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: March 1, 2022
    Inventors: Marianne Stanford, Genevieve Weir, Frederic Ors, Leeladhar Sammatur
  • Patent number: 11261259
    Abstract: Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: March 1, 2022
    Assignees: I-Mab Biopharma US Limited, ABL Bio Inc.
    Inventors: Wenqing Jiang, Lei Fang, Zhengyi Wang, Bingshi Guo, Eunyoung Park, Eunsil Sung, Byungje Sung
  • Patent number: 11242407
    Abstract: The present disclosure provides antibodies (e.g., humanized antibodies) that specifically bind to Mer Tyrosine Kinase (MERTK; e.g., human MERTK) and compositions comprising such antibodies. The present disclosure also provides antibody-drug conjugates comprising (i) an anti-MERTK antibody or antigen-binding fragment thereof described herein that specifically binds to MERTK (e.g., human MERTK), and (ii) cytotoxic agents conjugated directly to the antibodies or conjugated to the antibodies via linkers, and compositions comprising such antibody-drug conjugates. The present disclosure also provides methods for treating cancer, comprising administering to a human subject in need thereof (a) an anti-MERTK antibody that specifically binds to MERTK (e.g., human MERTK) or an antigen-binding fragment thereof described herein, or (b) an antibody-drug conjugate that comprises (i) an anti-MERTK antibody or antigen-binding fragment thereof that specifically binds to MERTK (e.g.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: February 8, 2022
    Assignee: Inspirna, Inc.
    Inventors: Masoud Tavazoie, Isabel Kurth, Shugaku Takeda, Celia Andreu-Agullo, Ivo Lorenz
  • Patent number: 11230599
    Abstract: The present invention encompasses the discovery that the likelihood of a favorable response to cancer immunotherapy for a wide range of different cancers can be predicted through definition of a tumor mutational load threshold for the tumor (and/or the relevant immunotherapy).
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: January 25, 2022
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Timothy A. Chan, Diego Chowell Puente, Robert M. Samstein, Luc Morris
  • Patent number: 11224654
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: January 18, 2022
    Assignee: MORPHOSYS AG
    Inventors: Jan Endell, Mark Winderlich, Rainer Boxhammer
  • Patent number: 11219694
    Abstract: The subject matter described herein is directed to methods of modifying the micro-environment of a target cell or The methods comprise systemically administering to a subject a composition comprising a vector, wherein the vector comprises a construct for the expression of a trap in the target cell, wherein the trap is expressed in the target cell thereby modifiying the micro-environment. Also described herein are methods of reducing metastasis of a cancer comprising, systemically administering to a subject suffering from the cancer, a composition comprising a vector, wherein the vector comprises a construct for the expression of a trap, wherein the trap is delivered to and then expressed in tissue susceptible to metastasis, wherein metastasis of the cancer to the tissue is reduced. Compositions for carrying out the methods are also described.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: January 11, 2022
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Leaf Huang, Tyler Goodwin, Rihe Liu, Lei Miao